Close Menu

NEW YORK – Rheonix said on Tuesday that it has filed its first 501(k) to seek clearance for a molecular test system from the US Food and Drug Administration. The Ithaca, New York-based diagnostics maker is seeking authorization to market its PCR-based system along with a triplex test for a sexually transmitted infections.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.